Biotech firms specializing in messenger RNA (mRNA)-based therapeutics are reshaping the face of medicine and industry development timelines. With the rising need for personalized medicine and responsivity to emerging pandemic diseases such as COVID-19, this new development method allows for adaptability and efficiency, shortening the lead time for drug candidates.
While much of the focus is on accelerating approval, many companies overlook how to ensure speed to market safely after approval and during full production. Rapid microbial detection technology and rapid bacterial endotoxin tests can be effectively used for mRNA-based therapeutics, matching the speed of development with the speed of product quality testing.
mRNA therapies represent a new frontier in medicine with the potential to revolutionize the way we treat many previously untreatable conditions. Recently, they have gained urgent awareness and global attention as the front-runners in potential vaccines for SARS-CoV-2, more commonly known as COVID-19.
With dramatically shortened development timelines, cost-effective production techniques, and well-funded project plans, mRNA firms all have one critical driver to contend with: race to market.